Illumina Ventures published its industry segment report on liquid biopsies, with a particular focus on oncology. This report offers high-level insights into the current trends, market growth and technological advancements shaping the industry. It provides a breakdown of current products and research surrounding early detection for single-cancers and multi-cancers, therapy selection and response, and minimal residual disease monitoring.

Liquid biopsy is becoming one of the core diagnostic elements in oncology and beyond. It has potential to revolutionize cancer diagnostics and treatment by offering a less invasive, more efficient approach to detecting genetic mutations and monitoring disease progression. Click here to download the full report.

If you would be interested in learning more about the report findings and what it means for the future of cancer care, please don't hesitate to contact us at info@illuminaventures.com.